See more : Ataa Educational Company (4292.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Novan, Inc. (NOVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novan, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kismet Acquisition Two Corp. (KAIIW) Income Statement Analysis – Financial Results
- I-Minerals Inc. (IMAHF) Income Statement Analysis – Financial Results
- PT Voksel Electric Tbk (VOKS.JK) Income Statement Analysis – Financial Results
- Stratabound Minerals Corp. (SBMIF) Income Statement Analysis – Financial Results
- Kiran Print-Pack Limited (KIRANPR.BO) Income Statement Analysis – Financial Results
Novan, Inc. (NOVN)
About Novan, Inc.
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.61M | 2.82M | 4.21M | 4.48M | 5.99M | 2.14M | 0.00 | 0.00 | 112.00K |
| Cost of Revenue | 7.38M | 0.00 | 0.00 | 25.17M | 23.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 16.23M | 2.82M | 4.21M | -20.70M | -17.05M | 2.14M | 0.00 | 0.00 | 112.00K |
| Gross Profit Ratio | 68.74% | 100.00% | 100.00% | -462.25% | -284.66% | 100.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 15.99M | 20.42M | 19.81M | 25.17M | 23.05M | 25.21M | 46.49M | 16.57M | 6.77M |
| General & Administrative | 0.00 | 12.34M | 11.27M | 10.41M | 11.51M | 0.00 | 13.34M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.10M | 12.34M | 11.27M | 10.41M | 11.51M | 13.11M | 13.34M | 9.27M | 5.17M |
| Other Expenses | 1.53M | -136.00K | -712.00K | -419.00K | 72.00K | 0.00 | 127.00K | 0.00 | 0.00 |
| Operating Expenses | 51.62M | 32.62M | 30.37M | 35.17M | 34.55M | 38.33M | 59.83M | 25.83M | 11.94M |
| Cost & Expenses | 59.00M | 32.62M | 30.37M | 35.17M | 34.55M | 38.33M | 59.83M | 25.83M | 11.94M |
| Interest Income | 53.00K | 13.00K | 51.00K | 177.00K | 297.00K | 0.00 | 81.00K | 48.00K | 58.00K |
| Interest Expense | 1.45M | 0.00 | 0.00 | 2.00K | 1.05M | 0.00 | 2.00K | 1.00K | 701.00K |
| Depreciation & Amortization | 1.63M | -384.00K | 6.14M | 2.35M | 1.66M | 1.42M | 757.00K | 631.00K | 462.00K |
| EBITDA | -33.76M | -30.30M | -24.07M | -28.34M | -26.53M | -33.82M | -59.83M | -25.16M | -11.31M |
| EBITDA Ratio | -142.99% | -1,073.67% | -572.10% | -633.06% | -442.80% | -1,580.37% | 0.00% | 0.00% | -10,096.43% |
| Operating Income | -35.39M | -29.92M | -30.21M | -30.69M | -28.56M | -36.19M | -59.83M | -25.83M | -11.83M |
| Operating Income Ratio | -149.90% | -1,060.06% | -718.01% | -685.46% | -476.73% | -1,690.89% | 0.00% | 0.00% | -10,560.71% |
| Total Other Income/Expenses | 4.08M | 223.00K | 921.00K | 47.00K | 0.00 | -942.00K | 127.00K | 48.00K | -1.28M |
| Income Before Tax | -31.31M | -29.69M | -29.29M | -30.64M | -12.67M | -37.13M | -59.70M | -25.79M | -13.10M |
| Income Before Tax Ratio | -132.62% | -1,052.16% | -696.13% | -684.41% | -211.53% | -1,734.91% | 0.00% | 0.00% | -11,699.11% |
| Income Tax Expense | -11.75M | -855.00K | 870.00K | 138.00K | -15.89M | 942.00K | -757.00K | 2.28M | -1.01M |
| Net Income | -19.56M | -28.84M | -30.16M | -30.78M | -12.67M | -37.13M | -59.70M | -28.06M | -11.39M |
| Net Income Ratio | -82.85% | -1,021.86% | -716.80% | -687.49% | -211.53% | -1,734.91% | 0.00% | 0.00% | -10,167.86% |
| EPS | -0.89 | -1.69 | -3.05 | -11.72 | -4.91 | -23.23 | -99.73 | -25.11 | -10.19 |
| EPS Diluted | -0.89 | -1.69 | -3.05 | -11.72 | -4.91 | -23.23 | -99.73 | -25.11 | -10.19 |
| Weighted Avg Shares Out | 22.02M | 17.07M | 9.88M | 2.63M | 2.58M | 1.60M | 598.60K | 1.12M | 1.12M |
| Weighted Avg Shares Out (Dil) | 22.02M | 17.07M | 9.88M | 2.63M | 2.58M | 1.60M | 598.60K | 1.12M | 1.12M |
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology
Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q1 2022 Results - Earnings Call Transcript
Novan to Report First Quarter 2022 Financial Results on May 16, 2022
Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q4 2021 Results - Earnings Call Transcript
Novan to Report Full Year 2021 Financial Results on February 22, 2022
Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206
Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
Novan Announces Strategic Priorities and Outlines Key Milestones
Novan Engages Syneos Health as Commercial Solutions Provider for SB206
Novan to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Source: https://incomestatements.info
Category: Stock Reports